Pricing Log in Create free account

Moleculin Biotech, Inc. (MBRX) vs Tempest Therapeutics, Inc. (TPST)

Moleculin Biotech, Inc. and Tempest Therapeutics, Inc. are both Biotechnology companies. Moleculin Biotech, Inc. is the larger, with a market value of $9.2M against $7.5M — 1.2× the size. Tempest Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Moleculin Biotech, Inc. trades at 0.0×. Across the 8 metrics below, Moleculin Biotech, Inc. leads on 4 and Tempest Therapeutics, Inc. on 4.

Valuation

Metric MBRX TPST Biotechnology median
P/E 0.04 n/m 10.26
P/S n/m 17.86 9.18
P/B 0.21 n/m 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 0.16 n/m 0.65
EV/Sales n/m 22.37 8.98
Earnings yield 2,573.95% (1,178.26%) (34.89%)
Free cash flow yield (1,027.71%) (365.85%) (24.52%)

Profitability

Metric MBRX TPST Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (1,471.05%) (931.14%) (50.12%)
Return on assets (152.41%) (237.25%) (45.60%)
Return on invested capital (417.27%) 0.00% 0.00%

Growth

Metric MBRX TPST Biotechnology median
Revenue growth (TTM) — (52.98%) 6.26%
EPS growth (last fiscal year) 82.01% 67.55% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MBRX TPST Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.94 0.38 4.89
Net debt to EBITDA 0.35 0.29 1.01

Dividend

Metric MBRX TPST Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MBRX TPST Biotechnology median
Market cap 9.16m 7.50m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack